Welcome to our dedicated page for Ross Acquisition Ii news (Ticker: ROSS), a resource for investors and traders seeking the latest updates and insights on Ross Acquisition Ii stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ross Acquisition Ii's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ross Acquisition Ii's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ROSS Acquisition Corp II (NYSE: ROSS,WS) has entered into a definitive agreement to merge with APRINOIA Therapeutics, a clinical-stage biotech focused on neurodegenerative diseases. The transaction is valued at $280 million, with funding aimed at advancing APRINOIA's therapeutic programs, including its lead product, APN-1607. The merger, expected to close in the first half of 2023, will create a publicly traded entity on Nasdaq or NYSE. APRINOIA holds agreements with major biotech firms such as Biogen, and anticipates significant market opportunities in treating Alzheimer’s Disease, which affects an estimated 10 million individuals in China alone.
On May 27, 2021, Ross Acquisition Corp II (NYSE: ROSS) announced it regained compliance with NYSE regulations after filing its Form 10-Q for the quarter ended March 31, 2021. This filing came after receiving a notice from the NYSE on May 25, 2021, indicating non-compliance due to a delayed filing. The NYSE gave the company six months to rectify the issue. The compliance reinstatement means the listing of ROSS on the NYSE remains unaffected.